In this strange new COVID-19 world, there’s one major question on many people’s minds: When will it all end? The majority of people in the U.S.—as well as across the globe—are under some type of lockdown order. That means you’re spending all your time at home these days, unless you’re an essential worker.
The unsettling reality is that no one knows how long it will take for life to get back to normal—and we won’t know, says Dr. Rashid Chotani, until widespread testing is made available to confirm who’s positive out there. “Widespread testing is what enables us to discern disease incidence and prevalence, and to determine who has recovered from infection,” explains Chotani, the vice president of Medical Affairs at CareLife Medical.
It seems World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus shares this view. On April 15 he tweeted: “One of the main things we've learned in the past months about COVID-19 is that the faster all cases are found, tested, isolated & cared for, the harder we make it for the virus to spread. This principle will save lives & mitigate the economic impact of the pandemic.”
Antibody testing may help do this, and more. That’s because there is still so much to discover about the novel coronavirus (it has only been infecting humans for four months, after all). Many researchers suspect that if it behaves like most other viruses do, the presence of post-infection antibodies in our bloodstreams may provide some level of immunity—and hopefully allow us to return to our regular lives.
What Are Antibodies, Anyway?
When you catch a virus, your body starts working immediately to counteract it. Your white blood cells produce proteins called antibodies in response to the infection, whose main job is to kick this "invader" out of your system. “The presence of an antibody indicates that someone has been exposed to that pathogen at some point,” says John Schmitz, Ph.D., associate director of the Clinical Microbiology/Immunology Laboratories at UNC Hospitals in Chapel Hill, NC.
Two types of antibodies in particular are important indicators for COVID-19. (They are produced in response to a variety of different infections—coronavirus is just one example.)
- IgM (short for “immunoglobulin M”) indicates that someone was recently exposed or is currently fighting off an active infection.
- IgG (you guessed it–“immunoglobulin G”) develops later on, and it shows that you’ve developed an immune response to the virus. Whereas IgM peaks and fades within a matter of weeks, IgG can sometimes last for months or even years to provide some level of protection from re-infection.
The level of protection these antibodies provide depends on the specific virus—and for COVID-19, scientists still aren’t sure whether immunity develops this way. But the hope is that these antibodies might indicate at least some level of protection against COVID-19, once someone has recovered from illness.
The important word there is might. On April 17, Dr. Michael Ryan, executive director of the WHO Health Emergencies Program, warned that “nobody is sure whether someone with antibodies is fully protected against having the disease or being exposed again.” Scientists and health officials hope to know more in the coming weeks and months.
Is Antibody Testing Available in the U.S.?
In order to know if you have the anitbodies for COVID-19, you need a test for them, and antibody testing is just beginning to roll out in this country. Unlike polymerase chain reaction (PCR) nasal swab testing, which tells you if you currently have COVID-19, antibody tests have the potential to tell us who has already recovered from the virus—even if such individuals never showed any symptoms, which occurs in up to 25% of all cases, according to the Centers for Disease Control and Prevention (CDC). This is especially important for us to learn to help stop community spread among people whose symptoms are so mild they might not know they have COVID-19 in the first place—but are continuing to engage with others, potentially transmitting the disease.
This is a really big deal. “The faster we can clear individuals from active disease state, the faster we can mitigate the socio-economic downturn and social disruption,“ explains Dr. Rashid Chotani, vice president of Medical Affairs at CareLife Medical. In other words, the more people we can test, the more experts will know about when it’s safe to reopen the economy again.
How Is the Antibody Test Done?
Karen Dukess, 57, is an author and mom of two living in New Rochelle, NY. She developed suspicious symptoms in early March, headed to Greenwich Hospital in Connecticut (under the instructions of her doctor) to do a drive-through test, and found out she was positive for COVID-19 on March 10.
Luckily, Dukess recovered at home within several weeks. She then immediately signed up to get her blood tested for antibodies at Mount Sinai Hospital in Manhattan. She arrived at the facility on April 2, where she was given a mask and got a temperature check at the door. “There were a lot of people there, two waiting rooms,” she remembers, describing how people were purposefully kept at a distance from one another.
Dukess got her blood drawn and did a PCR test, to make sure she no longer had an active infection. Two days later, she was informed that she did have resistant antibodies to COVID-19. But to her surprise, she also tested positive once again for COVID-19 through the nose swab, even though she no longer felt sick. One week later, on April 10, she returned to Mount Sinai for a final nose swab test to confirm the virus was no longer present in her RNA—and, finally, she tested negative. Which cleared her for the next step: donating her plasma.
What Is Convalescent Plasma, and Why Might It Help?
Plasma is the medical term for the golden-colored part of blood containing antibodies, and it’s important because scientists can use it to study the COVID-19 resistant antibodies from recovered patients. Again, at this time it’s unclear whether antibodies indicate immunity—and that’s what scientists are working around the clock to find out. Since such antibodies may hold the key to ending the coronavirus pandemic, survivors are being asked to donate blood or plasma for research purposes.
Whats more, the FDA is encouraging those who have recovered from COVID-19 to donate convalescent plasma in the hopes that it can be used to treat seriously ill patients, by reinjecting it into their bloodstreams to boost their immune response. When you donate plasma, a healthcare provider will draw your blood, put it into a machine to separate out the plasma, then reinject the rest of the blood back into your arm. This is still an experimental approach in the clinical trials stage, but it has been used successfully during other epidemics such as SARS, MERS, and H1N1.
Dukess is hoping to donate her plasma at Mount Sinai, but she’s still waiting to hear back for follow-up instructions. In the meantime, she responded to a request for blood donors from Rockefeller University in Manhattan to participate in a series of studies on prevention and treatment of the virus. Researchers at Rockefeller are looking for “elite neutralizers,” a fancy term for antibodies so resistant to COVID-19 that they could be used to make a drug. In other words, scientists believe that a small group of people may have battled the virus so effectively that their antibodies could help create a cure.
On April 17, Dukess arrived at Rockefeller to donate blood. The campus was nearly empty. The nurses took her vitals, did a finger-prick hemoglobin test, and then drew about half a bag of blood. “It was frankly one of the most exciting days I’ve had in weeks, because I got to go somewhere and see so many people,” she says. “It felt good to do something useful.” She hopes her early experience with the virus can ultimately help keep other people safe.
Can I Become an Antibody Donor?
If you’re a recovered COVID-19 patient (or you believe you may have had the virus), you may be able to donate blood or plasma to help with research efforts. The FDA’s website provides information about where you can donate, and from there, you can contact a representative in your area.
While still new, antibody testing and experimental treatments hold promise. “The ability to identify individuals who are IgM-negative and IgG-positive is critical if we are to return to some normalcy and reassure labor force mobility,” Dr. Chotani says. Schmitz’s team at UNC is currently working to figure out which model of antibody testing is most accurate and able to be used at high volume. “Widespread testing is going to be needed in order to safely allow stay-at-home mandates to be lessened,” he says. And that’s something worth waiting for.